If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

EPT Disclosure

9 Aug 2005 15:25

UBS AG (EPT)09 August 2005 This announcement replaces the previous RNS announcement reference 7900Preleased at 11:58 on 5 Aug 05. Amendment made to the BUY figures of BPB PLC dueto the late entry of a trade. All other information remains unchanged. FORM 38.5 DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS (Rule 38.5 of The City Code on Takeovers and Mergers) Name of exempt principal trader UBS AG Company dealt in TOREX RETAIL PLC Relevant security dealt in ORDINARY SHARES 1P Name of offeree/offeror with whom connected TOREX RETAIL PLC Nature of connection # FINANCIAL ADVISER Date of dealing 03 August 2005 Total number of securities bought 2,590 Highest price paid (currency must be stated) 1.13 GBP Lowest price paid (currency must be stated) 1.13 GBP Total number of securities sold 0 Highest price paid (currency must be stated) 0 GBP Lowest price paid (currency must be stated) 0 GBP Date of disclosure 04 August 2005 Contact name ROBIN RAGNUTH Telephone number 020 7567 8289 # See the definition of "connected fund managers and principal traders" in theDefinitions Section of the Code. For details of the Code's dealing disclosure requirements, see Rules 8 and 38.5and their Notes which can be viewed on the Takeover Panel's website atwww.thetakeoverpanel.org.uk. FORM 38.5 DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS (Rule 38.5 of The City Code on Takeovers and Mergers) Name of exempt principal trader UBS AG Company dealt in BPB PLC Relevant security dealt in ORDINARY SHARES 50P Name of offeree/offeror with whom connected COMPAGNIE DE SAINT-GOBAIN Nature of connection # FINANCIAL ADVISER Date of dealing 03 August 2005 Total number of securities bought 17,198,046 Highest price paid (currency must be stated) 7.3950 GBP Lowest price paid (currency must be stated) 6.8550 GBP Total number of securities sold 18,806,741 Highest price paid (currency must be stated) 7.4000 GBP Lowest price paid (currency must be stated) 6.9200 GBP Date of disclosure 04 August 2005 Contact name ROBIN RAGNUTH Telephone number 020 7567 8289 # See the definition of "connected fund managers and principal traders" in theDefinitions Section of the Code. For details of the Code's dealing disclosure requirements, see Rules 8 and 38.5and their Notes which can be viewed on the Takeover Panel's website atwww.thetakeoverpanel.org.uk. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
30th Mar 20207:00 amRNSUpdate in relation to working capital position
20th Mar 20207:00 amRNSDirectorate Change
6th Feb 20207:15 amEQSHardman & Co Research: Tissue Regenix (TRX): Restructured to satisfy product demand
4th Feb 202011:47 amRNSResolution of Cyber Security Incident
28th Jan 202010:02 amRNSNotice of cyber security incident
22nd Jan 20207:00 amRNSTrading Update
14th Jan 20204:40 pmRNSSecond Price Monitoring Extn
14th Jan 20204:35 pmRNSPrice Monitoring Extension
21st Nov 20194:35 pmRNSPrice Monitoring Extension
18th Nov 20194:03 pmRNSDirectorate Change
14th Nov 20194:00 pmRNSHolding(s) in Company
14th Nov 20197:00 amRNSUpdated loan facility agreement with MidCap
13th Nov 20193:35 pmRNSHolding(s) in Company
13th Nov 20193:17 pmRNSHolding(s) in Company
11th Nov 20192:05 pmRNSSecond Price Monitoring Extn
11th Nov 20192:00 pmRNSPrice Monitoring Extension
11th Nov 20197:00 amRNSUpdate in relation to loan facility
17th Oct 20194:27 pmRNSHolding(s) in Company
17th Oct 20197:00 amRNSTrading Update
15th Oct 20193:27 pmRNSHolding(s) in Company
3rd Oct 20197:00 amRNSDermaPure Product Line Extension Launched
10th Sep 20197:00 amRNSUnaudited Interim Results
28th Aug 20197:00 amRNSAppointment of CFO
15th Aug 20197:00 amRNSAdditional manufacturing capacity secured
1st Aug 20197:00 amRNSDirectorate Change
8th Jul 20195:03 pmRNSHolding(s) in Company
20th Jun 20192:23 pmEQSHardman & Co Research: Tissue Regenix (TRX): Credit facilities expand cash runway to 2021
7th Jun 20192:55 pmRNSIssue of Equity and Total Voting Rights
4th Jun 20197:00 amRNSNotice of AGM
4th Jun 20197:00 amRNSSecures Credit Facilities of up to $20m
4th Jun 20197:00 amRNSAnnual Results for the year ended 31 December 2018
21st May 20197:00 amRNSCEO to return to full time duties
10th Apr 20197:20 amEQSHardman & Co Research: Tissue Regenix (TRX): Expanded GPO coverage secured
4th Apr 20197:26 amRNSExpands US GPO coverage for DermaPure
18th Feb 20197:00 amRNSChange of Adviser
6th Feb 201911:05 amRNSSecond Price Monitoring Extn
6th Feb 201911:00 amRNSPrice Monitoring Extension
4th Feb 20197:00 amRNSTrading Update
17th Dec 201811:56 amEQSHardman & Co Research: Tissue Regenix (TRX): 2018 in review: foundations laid for osteobiologics
6th Dec 20187:00 amRNSInterim Management Change
13th Nov 20187:00 amRNSPan European distribution agreement with Arthrex
29th Oct 20187:00 amRNSGareth Jones commences position as CFO
14th Sep 20187:16 amEQSHardman & Co Research: Tissue Regenix (TRX): Strategy delivering growth above expectations
3rd Sep 20187:00 amRNSUnaudited Interim Results
2nd Aug 201810:10 amEQSHardman & Co Research: Tissue Regenix (TRX): 1H'18 preview: organic plus inorganic growth
2nd Aug 20187:00 amRNSNotice of Interim Results
4th Jul 20187:00 amRNSAppointment of CFO
25th Jun 20187:00 amRNSHTA License granted and UK distribution Agreement
21st Jun 20187:10 amRNSTRX BioSurgery wins GPO Supplier Horizon Award
18th Jun 20187:00 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.